Carbenoxolone reduces cyclic nucleotides level, destabilizes maturation promoting factor and induces meiotic exit

Meenakshi Tiwari1, Shail K Chaube1

  • 1Cell Physiology Laboratory, Department of Zoology, Institute of Science, Banaras Hindu University, Varanasi-221005, UP, India.

Abstract

Insights

Carbenoxolone (CBX) blocks gap junctions, reducing cyclic nucleotides and destabilizing maturation promoting factor (MPF) to induce meiotic exit from diplotene arrest (EDA) in rat oocytes. This finding suggests CBX could aid in assisted reproductive technology (ART) programs.

Area of Science:

  • Reproductive Biology
  • Cell Signaling
  • Developmental Biology

Background:

  • Meiotic exit from diplotene arrest (EDA) in mammals is linked to gap junction disruption and cyclic nucleotide transfer to the oocyte.
  • Gap junctions facilitate communication between cumulus cells and oocytes, influencing meiotic progression.

Purpose of the Study:

  • To investigate if carbenoxolone (CBX), a gap junction blocker, can induce EDA in rat oocytes.
  • To determine if CBX reduces cyclic nucleotide levels and destabilizes maturation promoting factor (MPF) in vitro.

Main Methods:

  • Rat oocytes at diplotene arrest were cultured with varying concentrations of CBX.
  • Analysis included morphological changes, meiotic status, nitric oxide synthase (iNOS), cyclic nucleotides (cAMP, cGMP), Cdc25B, and Cdk1/cyclin B1 phosphorylation status.

Main Results:

  • CBX induced EDA in a concentration-dependent manner.
  • CBX significantly decreased iNOS, nitric oxide, and cyclic nucleotide levels, leading to reduced Cdc25B expression.
  • CBX destabilized MPF by altering Cdk1 phosphorylation and reducing cyclin B1 levels, ultimately inducing EDA.

Conclusions:

  • CBX blocks gap junctions, interrupting cyclic nucleotide transfer and destabilizing MPF, thereby inducing EDA in vitro.
  • CBX shows potential for inducing meiotic maturation in oocytes for assisted reproductive technology (ART).

Related Concept Videos

Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.1K
Meiosis II02:02

Meiosis II

Meiosis II entails cell division and segregation of the sister chromatids, resulting in the production of four unique haploid gametes. The steps for meiosis II are similar to mitosis, except that meiosis II occurs in haploid cells, whereas mitosis occurs in diploid cells.
The timing and cell division patterns of meiosis differ between males and females. In male meiosis, the centrosomes are part of the formation of the meiotic spindle. However, in oocytes, including that of humans, Drosophila,...
50.5K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K